Topical timolol appears to provide a curative effect in managing chronic ulcers. However, the pooled evidence of its effect hasn’t been established yet. This is the first Meta-analysis to evaluate and assess the efficacy of topical timolol in accelerating wound healing in patients with chronic refractory ulcers.
Methods
We comprehensively searched different electronic databases; PubMed, Scopus, Web of Science, Cochrane library and ClinicalTrials.gov from their inception to November 2024. The search was conducted without imposing any restrictions on publication date or study design. The ROB-II tool was used to assess the quality of included RCTs. NIH tools were used to evaluate the quality of included cohort and single arm studies. Risk ratios (RR) and mean differences (MD), with 95% confidence intervals (CIs), were used as effect estimates.
Results
Six studies were included in this systematic review, comprising two single-arm studies and four double-arm studies (3 RCTs and 1 cohort study). Data from the four double-arm studies on venous ulcers were pooled for meta-analysis. The results showed that topical timolol significantly reduced ulcer area compared to control at 2 weeks (−23.63%; 95% CI: −29.26 to −18.00; p < 0.00001), 4 weeks (−41.40%; 95% CI: −49.57 to −33.23; p < 0.00001), and 12 weeks (−23.38%; 95% CI: −39.43 to −7.33; p = 0.004). Complete ulcer healing was observed at 4 weeks (RR: 12.00; 95% CI: 1.68 to 85.84; p = 0.01) and 12 weeks (RR: 3.79; 95% CI: 0.44 to 32.54; p = 0.22).
Conclusion
Topical timolol has the potential to promote healing in chronic unhealed ulcers. This meta-analysis, focusing on chronic venous ulcers, consistently showed favorable results across different time points. However, the small sample sizes, lack of blinding, and inclusion of only four studies limit the generalizability of the findings.
PastarIBalukoffNCMarjanovicJChenVYStoneRCTomic-CanicM. Molecular pathophysiology of chronic wounds: Current state and future directions. Cold Spring Harb Perspect Biol. 2023;15(4):a041243. doi:https://doi.org/10.1101/cshperspect.a041243
2.
EmingSAMartinPTomic-CanicM. Wound repair and regeneration: Mechanisms, signaling, and translation. Sci Transl Med. 2014;6(265). doi:https://doi.org/10.1126/scitranslmed.3009337
RichmondNAMaderalADVivasAC. Evidence-based management of common chronic lower extremity ulcers: Management of chronic lower extremity ulcers. Dermatol Ther. 2013;26(3):187-196. doi:https://doi.org/10.1111/dth.12051
6.
AgaleSV. Chronic leg ulcers: Epidemiology, aetiopathogenesis, and management. Ulcers. 2013;2013:1-9. doi:https://doi.org/10.1155/2013/413604
7.
PetersenBJRothenbergGMLakhaniPJ, et al.Ulcer metastasis? Anatomical locations of recurrence for patients in diabetic foot remission. J Foot Ankle Res. 2020;13(1):1. doi:https://doi.org/10.1186/s13047-020-0369-3
8.
ArmstrongDGBoultonAJMBusSA. Diabetic foot ulcers and their recurrence. Ingelfinger JR, ed. N Engl J Med. 2017;376(24):2367-2375. doi:https://doi.org/10.1056/NEJMra1615439
9.
SchultzGBjarnsholtTJamesGA, et al.Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Repair Regen. 2017;25(5):744-757. doi:https://doi.org/10.1111/wrr.12590
10.
FalangaV. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2000;8(5):347-352.
SivamaniRKShiBGriffithsE, et al.Acute wounding alters the Beta2-adrenergic signaling and catecholamine synthetic pathways in keratinocytes. J Invest Dermatol. 2014;134(8):2258-2266. doi:https://doi.org/10.1038/jid.2014.137
13.
McGrawDW. Molecular mechanisms of 2-adrenergic receptor function and regulation. Proc Am Thorac Soc. 2005;2(4):292-296. doi:https://doi.org/10.1513/pats.200504-027SR
Lev-TovHDahleSMossJIsseroffRR. Successful treatment of a chronic venous leg ulcer using a topical beta-blocker. J Am Acad Dermatol. 2013;69(4):e204-e205. doi:https://doi.org/10.1016/j.jaad.2013.06.003
16.
ManahanMNPetersPScuderiSSurjanaDBeardmoreGL. Topical timolol for a chronic ulcer — a case with its own control. Med J Aust. 2014;200(1):49-50. doi:https://doi.org/10.5694/mja13.10823
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J.2021;n71, Published online March 29, 2021:n71. doi:https://doi.org/10.1136/bmj.n71.
19.
CumpstonMLiTPageMJ, et al.Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Editorial Unit, ed. Cochrane Database Syst Rev. 2019. Published online October 3, 2019. doi:https://doi.org/10.1002/14651858.ED000142
20.
SchardtCAdamsMBOwensTKeitzSFonteloP. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7(1):16. doi:https://doi.org/10.1186/1472-6947-7-16
21.
SterneJACSavovićJPageMJ, et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J.2019;l4898, Published online August 28, 2019:l4898. doi:https://doi.org/10.1136/bmj.l4898.
22.
TawfikGMDilaKASMohamedMYF, et al.A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47(1):46. doi:https://doi.org/10.1186/s41182-019-0165-6
23.
McGuinnessLAHigginsJPT. Risk-of-bias VISualization (robvis): An R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55-61. doi:https://doi.org/10.1002/jrsm.1411
SchrollJBMoustgaardRGøtzschePC. Dealing with substantial heterogeneity in cochrane reviews. Cross-sectional study. BMC Med Res Methodol. 2011;11(1):22. doi:https://doi.org/10.1186/1471-2288-11-22
26.
EggerMSmithGDSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. Br Med J.1997;315(7109):629-634. doi:https://doi.org/10.1136/bmj.315.7109.629
27.
RaiAKJananiKRaiR. Efficacy of topical timolol versus saline in chronic venous ulcers: A randomized controlled trial. J Cutan Aesthetic Surg. 2020;13(1):18-23. doi:https://doi.org/10.4103/JCAS.JCAS_13_19
28.
SinghKRaza FarooquiMMatharooPSainiM. Comparative evaluation of timolol vs saline in the treatment of chronic venous ulcer. Published online 2021. Accessed January 7, 2025. https://www.worldwidejournals.com/international-journal-of-scientific-research-(IJSR)/article/comparative-evaluation-of-timolol-vs-saline-in-the-treatment-of-chronic-venous-ulcer/Mzc5ODY=/?is=1&b1=717&k=180.
29.
BaltazardTSenetPMomarD, et al.Evaluation of timolol maleate gel for management of hard-to-heal chronic venous leg ulcers. Phase II randomised-controlled study. Ann Dermatol Vénéréologie. 2021;148(4):228-232. doi:https://doi.org/10.1016/j.annder.2020.11.009
30.
ThomasBKurienJSJoseTUlahannanSEVargheseSA. Topical timolol promotes healing of chronic leg ulcer. J Vasc Surg Venous Lymphat Disord. 2017;5(6):844-850. doi:https://doi.org/10.1016/j.jvsv.2017.04.019
31.
CahnBKaurRHirtP, et al.Use of topical timolol maleate as Re-epithelialization agent for treatment of recalcitrant wounds of varying etiologies. J Drugs Dermatol. 2020;19(12):1252-1256. doi:https://doi.org/10.36849/JDD.2020.5306
32.
MenezesJVFSenthamizhanS. Utility of topical timolol in the management of chronic non-healing foot ulcers. Int Surg J. 2023;10(4):663-667. doi:https://doi.org/10.18203/2349-2902.isj20230973
33.
PullarCERizzoAIsseroffRR. β-Adrenergic receptor antagonists accelerate skin wound healing: EVIDENCE FOR A CATECHOLAMINE SYNTHESIS NETWORK IN THE EPIDERMIS*. J Biol Chem. 2006;281(30):21225-21235. doi:https://doi.org/10.1074/jbc.M601007200
34.
LiangYJChenDWWenXRHuangBGaoYRanXW. [Successful treatment of refractory ischemic diabetic foot ulcers by combination therapy of autologous platelet-rich gel and topical β adrenergic receptor blocker: A case report]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020;51(4):582-586. doi:https://doi.org/10.12182/20200460601
BogomoletsOWierzbik-StrońskaMHryshchenkoRBogomoletsC. Urgent treatment of complicated ulcerated infantile hemangioma with β-blockers via telemedicine: A case report. Telemed J E-Health Off J Am Telemed Assoc. 2024;30(3):881-884. doi:https://doi.org/10.1089/tmj.2023.0338
37.
AlsaadAMSAlsaadSMFathaddinAAl-KhenaizanS. Topical timolol for vasculitis ulcer: A potential healing approach. JAAD Case Rep. 2019;5(9):812-814. doi:https://doi.org/10.1016/j.jdcr.2019.07.016
38.
AlmebayadhM. Successful treatment of ulcerated infantile hemangioma with brimonidine-timolol cream: 2 cases report and review of the literature. J Dermatol Treat. 2020;31(4):433-434. doi:https://doi.org/10.1080/09546634.2019.1603991
Muñoz-GarzaFZRíosMRoé-CrespoE, et al.Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage: A randomized clinical trial. JAMA Dermatol. 2021;157(5):583. doi:https://doi.org/10.1001/jamadermatol.2021.0596
41.
PüttgenKLuckyAAdamsD, et al.Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016;138(3):e20160355. doi:https://doi.org/10.1542/peds.2016-0355
42.
GhanbarzamaniASalehifarEJafariradA, et al.Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site. Iran J Pharm Res. 2021;20(3). doi:https://doi.org/10.22037/ijpr.2020.114565.14915
43.
DabiriGTigerJGoreshiRFischerAIwamotoS. Topical timolol may improve overall scar cosmesis in acute surgical wounds. Cutis. 2017;100(1):E27-E28.
44.
MohammadiAABakhshaeekiaAAlibeigiP, et al.Efficacy of Propranolol in Wound Healing for Hospitalized Burn Patients. J Burn Care Res. 2009;PAP. doi:https://doi.org/10.1097/BCR.0b013e3181b48600
RastogiAKulkarniSAAgarwalS, et al.Topical esmolol hydrochloride as a novel treatment modality for diabetic foot ulcers: A phase 3 randomized clinical trial. JAMA Netw Open. 2023;6(5):e2311509. doi:https://doi.org/10.1001/jamanetworkopen.2023.11509
47.
KulkarniSADeshpandeSKRastogiA. Novel topical esmolol hydrochloride improves wound healing in diabetes by inhibiting aldose reductase, generation of advanced glycation end products, and facilitating the migration of fibroblasts. Front Endocrinol. 2022;13:926129. doi:https://doi.org/10.3389/fendo.2022.926129
48.
VA Office of Research and Development. Beta Adrenergic Antagonist For The Healing of Chronic Diabetic Foot Ulcers. clinicaltrials.gov; 2024. Accessed January 7, 2025. https://clinicaltrials.gov/study/NCT03282981.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
